References
Cockfield, Lord. Written answer to the Commission of the European Communities. Official Journal of the European Community, Vol. 32, C138/13, 5.6.1989
Crombie IK, Brown SV, Hamley JG. Post marketing drug surveillance by record linkage in Tayside. Journal of Epidemiology and Communal Health 38: 226–231, 1984
Inman WHW. PEM News, No. 4, Drug Safety Research Unit, Southampton, 1987
Inman WHE, Rawson NSB, Wilton LV. Prescription event monitoring. In Inham (Ed.) Monitoring for drug safety, pp. 213–235, MTP Press Ltd, Lancaster, 1986
Joint Committee of ABPI, BMA, CSM and RCGP. Guidelines for post marketing surveillance. British Medical Journal 296: 340–399, 1988
Mann RD. The yellow card data: the nature and scale of the adverse drug reactions problem. In Mann (Ed.) Adverse drug reactions, pp. 5–66, Parthenon Publishing, Lancaster, 1987
Rawlins MD. Spontaneous reporting of adverse drug reactions I: the data, II: uses. British Journal of Clinical Pharmacology 26: 1–11, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bem, J.L., Wood, S.M., West, L. et al. 25 Years of the Committee on Safety of Medicines. Drug-Safety 5, 161–167 (1990). https://doi.org/10.2165/00002018-199005030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199005030-00001